Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Pfizer's (PFE) Omicron-Based COVID Shot Betters Immune Response
02:46pm, Monday, 27'th Jun 2022 Zacks Investment Research
Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.
Emergent's (EBS) Anthrax Vaccine BLA Gets FDA Acceptance
02:31pm, Monday, 27'th Jun 2022 Zacks Investment Research
The FDA accepts Emergent's (EBS) BLA seeking approval for its new anthrax vaccine, AV7909. A decision is expected in April next year.
Merck (MRK) Keytruda Gets Europe Nod for Expanded Melanoma Use
01:02pm, Monday, 27'th Jun 2022 Zacks Investment Research
European Commission approves Merck's (MRK) Keytruda as an adjuvant treatment for adults and adolescent patients with stage IIB or IIC melanoma and who have undergone complete resection.
Gilead (GILD) Announces Positive Data on Hepcludex for HDV
04:30pm, Friday, 24'th Jun 2022 Zacks Investment Research
Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.
Walgreens (WBA) to Report Q3 Earnings: What's in the Cards?
04:01pm, Friday, 24'th Jun 2022 Zacks Investment Research
Robust performances across the U.S. pharmacy and retail business are likely to have contributed to Walgreens' (WBA) Q3 performance.
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
02:08pm, Friday, 24'th Jun 2022 Zacks Investment Research
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051
01:45pm, Friday, 24'th Jun 2022 Zacks Investment Research
The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.
Tandem Diabetes (TNDM) Global Pump Sales Aid, Price Issue Ails
01:31pm, Friday, 24'th Jun 2022 Zacks Investment Research
Tandem Diabetes (TNDM) is witnessing strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Novartis' (NVS) Oncology Drugs Get Approval for Label Expansion
04:37pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Novartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
03:21pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Neogen's (NEOG) robust segmental performance and notable product launches instill investors' confidence.
Moderna (MRNA) Reveals New Data on Bivalent COVID Booster
02:06pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Moderna's (MRNA) bivalent COVID booster candidate exhibits a greater than a 5-fold boost in antibody responses against the Omicron subvariants BA.4 and BA.5 in a phase II/III study.
Merck's (MRK) Pneumococcal Vaccine Gets FDA Nod for Kids
12:39pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
Here's Why Investors Should Retain Tandem Diabetes (TNDM) Now
04:10pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Investors are optimistic about Tandem Diabetes' (TNDM) strong pump shipments and ongoing product innovations.
Walgreens (WBA) to Offer Health Services to Ohio Medicaid Members
04:04pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Walgreens' (WBA) subsidiary teams up with Buckeye Health Plan to provide wellness services through Walgreens Health Corner locations in Ohio.
National Vision (EYE) Gains on Volume Growth Amid Margin Woes
02:41pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
National Vision (EYE) plans to continue executing its core growth initiatives and further investing in strengthening competitive advantages.
